Saving the Lives of People with Blood Cancer
Graft vs Host Disease (GvHD) is a common complication for many patients during their recovery after a stem cell transplant. It’s caused by small differences between the new immune system and the patient’s other cells. This means the growing immune system may harm some of these cells because it sees them as ‘different’. It can…
by
A healthy gut We have known for a long time that our digestive system is home to billions of tiny microbes that help us digest our food properly. We are even encouraged to look after them by drinking “pro-biotic” products that we are told will aid our digestion. But recent research has shown that bacteria…
by
By David Marks, Medical Director of IMPACT. Stem cell transplants give a second chance of life to 4,400[i] people a year in the UK, but sadly, fewer than half of patients will reach the milestone of five-year survival. Much-needed improvements in patient outcomes can only be achieved through pioneering research. Clinical trials are crucial…
by
An Interview with Diana Hernandez, Anthony Nolan Research Institute’s Head of the Immunotherapy Group Tell us a bit about yourself and your background: My name is Diana Hernandez, and I have recently been appointed Head of the Immunotherapy Group at the Anthony Nolan Research Institute. Prior to my appointment here, I was Principal Scientist…
by
49-year-old Deborah lives in Drayton, North Worcestershire with her partner. She has two children and is the Public Health Director for Dudley. Deborah was diagnosed with acute myeloid leukaemia in January 2016. She was treated with chemotherapy and had a stem cell transplant in June 2016 and is currently participating in a clinical trial. …
by
An exciting new therapy for people with blood cancer has been approved for use in the USA. It involves collecting a patient’s own immune cells, modifying them to target cancer cells more efficiently and then injecting them back into the patient. The treatment, called Kymriah and produced by drug company Novartis, is one of many…
